Teva Pharmaceutical Industries (TEVA) DIvidends Date & History

Key Takeaways

• TEVA suspended dividends in December 2017, resulting in a current dividend yield of 0%.
• The company previously paid quarterly dividends, with the last payment of $0.085 per share in December 2017.
• Strong free cash flow generation, including $542 million recently, supports potential future dividend resumption.
• TEVA lags pharmaceutical peers like VTRS (3.29% yield) and PFE (6.37% yield).
• Focus on debt reduction and growth positions TEVA better for sustainable payouts down the line.
• Not ideal for current income investors but appealing for those eyeing long-term recovery.

Dividend Overview

Teva Pharmaceutical Industries (TEVA), a leading global generics and innovative medicines company, does not currently pay a dividend. The firm suspended its quarterly dividend payments in December 2017 to conserve cash amid high debt levels from past acquisitions and focus on operational turnaround. This results in a trailing annual dividend yield of 0% and a payout ratio of 0%. Prior to suspension, TEVA offered a modest yield with quarterly distributions. The 5-year average dividend yield stands at approximately 2.95%. With no ex-dividend date since November 27, 2017, TEVA is neither a dividend growth stock nor a high-yield play. Instead, it prioritizes reinvestment in its "Pivot to Growth" strategy, emphasizing innovative products and cost efficiencies.

Dividend History and Growth

TEVA maintained a consistent quarterly dividend policy from the late 1980s through 2017, with periodic increases reflecting business expansion. For instance, dividends grew steadily into the 2010s, supported by generics dominance. However, mounting debt from the 2016 Actavis acquisition led to financial strain, culminating in the 2017 suspension—no payments since the final $0.085 per ADS on December 12, 2017. There has been no dividend growth streak in recent years, and no cuts preceded the halt, but the suspension marked a strategic shift. Long-term, TEVA's history shows commitment to shareholders during prosperous periods, though current focus remains on balance sheet repair rather than resumption.

Dividend Sustainability and Payout Ratio

With no active dividend, sustainability metrics like payout ratio (0%) are not applicable. However, TEVA's financial health has improved markedly. In 2025, operating cash flow reached $1,649 million, up from $1,247 million prior year, while free cash flow hit $542 million. Debt reduction efforts continue, bolstering stability. Earnings coverage would be ample if dividends resume, given projected EPS growth. Elevated debt levels persist but are declining, and cost-saving programs (~$700 million through 2027) enhance flexibility. Overall, TEVA appears positioned to support a modest dividend in the future once leverage normalizes further.

Dividend Compared to Industry Peers

TEVA's 0% yield trails pharmaceutical industry peers significantly. Generics-focused VTRS (Viatris) offers 3.29%, while broader pharma giants like PFE (Pfizer) yield 6.37% and MRK (Merck) around 3-4%. The sector average hovers near 2-3%, with many firms balancing R&D spend and payouts. TEVA's absence reflects its recovery phase versus peers' mature profiles, making it less competitive for yield but potentially undervalued for growth-oriented income strategies.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover hidden gems like potential dividend resumers.

Is This Stock Attractive for Dividend Investors?

TEVA may not appeal to traditional dividend income investors seeking immediate yield, given its 0% payout and 2017 suspension. Conservative retirees or high-yield hunters would find better options among peers like PFE or VTRS. However, patient dividend growth enthusiasts could view TEVA favorably. Improving free cash flow ($542 million recently), rising revenues from innovative drugs like Austedo, and debt deleveraging signal a path to potential resumption. Long-term investors tolerant of volatility might position for future payouts, especially if "Pivot to Growth" delivers sustained profitability. Balance sheet strength and pipeline momentum enhance prospects, but timing remains uncertain—no resumption announced as of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations